Expert Opinion On Drug Safety

Scope & Guideline

Pioneering Insights for Safer Medications

Introduction

Delve into the academic richness of Expert Opinion On Drug Safety with our guidelines, detailing its aims and scope. Our resource identifies emerging and trending topics paving the way for new academic progress. We also provide insights into declining or waning topics, helping you stay informed about changing research landscapes. Evaluate highly cited topics and recent publications within these guidelines to align your work with influential scholarly trends.
LanguageEnglish
ISSN1474-0338
PublisherTAYLOR & FRANCIS LTD
Support Open AccessNo
CountryUnited Kingdom
TypeJournal
Convergefrom 2002 to 2024
AbbreviationEXPERT OPIN DRUG SAF / Expert Opin. Drug Saf.
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND

Aims and Scopes

Expert Opinion On Drug Safety focuses on the evaluation and analysis of drug safety profiles, particularly through pharmacovigilance studies. It aims to inform healthcare professionals and researchers about the risks and benefits associated with pharmaceutical therapies, utilizing real-world data and systematic reviews to derive insights into drug safety.
  1. Pharmacovigilance and Drug Safety Analysis:
    The journal emphasizes the importance of pharmacovigilance, aiming to monitor, assess, and understand adverse drug reactions and safety signals associated with various medications.
  2. Clinical Safety Evaluations:
    It provides comprehensive evaluations of drug safety through systematic reviews, meta-analyses, and real-world studies, offering insights into the efficacy and safety of drugs across multiple therapeutic areas.
  3. Risk-Benefit Assessments:
    The journal focuses on the balance between the therapeutic benefits of drugs and their potential risks, providing guidance for clinicians in making informed treatment decisions.
  4. Emerging Drug Safety Concerns:
    It addresses new and emerging safety concerns related to drugs, particularly in the context of novel therapies and changing treatment paradigms.
  5. Real-World Evidence Integration:
    The journal integrates real-world evidence to enhance understanding of drug safety in diverse populations and clinical settings, ensuring that findings are applicable to everyday medical practice.
The journal has witnessed the emergence of several key themes that reflect current trends in drug safety research. These themes highlight the evolving landscape of pharmacovigilance and the increasing complexity of drug safety evaluations.
  1. Real-World Evidence and Data Mining:
    There is a growing emphasis on utilizing real-world evidence and advanced data mining techniques to uncover adverse drug reactions and safety signals, reflecting a shift towards more data-driven approaches in pharmacovigilance.
  2. Machine Learning and Artificial Intelligence in Drug Safety:
    The integration of machine learning and AI technologies in pharmacovigilance is trending, with studies focusing on their potential to improve signal detection and risk assessment in drug safety.
  3. Patient-Centric Pharmacovigilance:
    An emerging focus on incorporating patient perspectives, experiences, and reported outcomes into drug safety evaluations is evident, aiming to enhance the relevance and applicability of findings.
  4. Safety of Novel Therapeutics and Biologics:
    Research is increasingly directed towards the safety profiles of novel therapeutics, including biologics and targeted therapies, particularly in oncology and immunology, reflecting the rapid advancement of these treatment modalities.
  5. Long-Term Safety and Post-Marketing Surveillance:
    There is a heightened interest in long-term safety studies and post-marketing surveillance, emphasizing the need to monitor drugs after they have been approved and widely prescribed.

Declining or Waning

As the field of drug safety evolves, certain themes within the journal have shown signs of declining prominence. This section highlights areas that are becoming less frequently addressed in recent publications.
  1. Traditional Pharmacovigilance Methods:
    There is a noticeable decline in studies focusing solely on traditional pharmacovigilance methods, as the field shifts towards more innovative and technology-driven approaches such as machine learning and big data analytics.
  2. Generalized Drug Safety Reviews:
    The trend towards more specialized and targeted safety evaluations has led to a decrease in broad, generalized reviews of drug safety, which may have been more common in earlier publications.
  3. Historical Drug Safety Studies:
    Research focusing on historical data or older medications is becoming less prevalent, as the journal increasingly prioritizes contemporary drugs and therapies.
  4. Single-Agent Safety Studies:
    There is a waning interest in studies examining the safety of single-agent therapies, with a growing focus on combination therapies and polypharmacy, especially in complex patient populations.
  5. Pharmacovigilance in Non-Pharmaceutical Contexts:
    The journal has seen a reduction in articles addressing pharmacovigilance in non-pharmaceutical contexts, such as dietary supplements or herbal products, which were previously more common.

Similar Journals

Journal of Young Pharmacists

Empowering Tomorrow's Pharmacists Today
Publisher: INPHARM ASSOC, PHCOG NETISSN: 0975-1483Frequency: 4 issues/year

Journal of Young Pharmacists is a distinguished peer-reviewed journal published by INPHARM ASSOCIATION in collaboration with PHCOG NET. With an ISSN of 0975-1483 and an E-ISSN of 0975-1505, this journal serves as a vital platform for disseminating pioneering research in the field of pharmacology and toxicology. Although coverage in Scopus was discontinued in 2018, the journal continues to be important in educating future pharmacists and advancing the discipline, evident from its ranking in the 29th percentile among general pharmacology journals. The Journal of Young Pharmacists seeks to bridge the gap between theoretical knowledge and practical application, encouraging young researchers, professionals, and students to contribute their insights and findings. The journal emphasizes innovative approaches and contemporary issues relevant to the pharmaceutical sciences, making it an invaluable resource for anyone involved in this dynamic field.

INDIAN JOURNAL OF PHARMACOLOGY

Bridging research and practice in the world of pharmacology.
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 0253-7613Frequency: 6 issues/year

INDIAN JOURNAL OF PHARMACOLOGY, published by Wolters Kluwer Medknow Publications, is a premier platform dedicated to advancing the field of pharmacology and its related disciplines. With a rich history since its inception in 1978, this journal aims to disseminate high-quality research findings, reviews, and clinical studies that contribute to the global understanding of drug action and therapeutic practices. As a valuable resource for researchers, professionals, and students alike, it operates within the Q3 quartile of the Pharmacology category, positioning itself as an influential contributor in the realm of medical pharmacology. The journal is committed to publishing rigorous scientific inquiry, fostering innovation, and bridging gaps between laboratory research and clinical application. Readers can access its wide-ranging articles to stay informed about the latest advancements in the field, reflecting its crucial role in shaping future pharmacological research and practice.

Therapeutics and Clinical Risk Management

Championing open access to critical therapeutic knowledge.
Publisher: DOVE MEDICAL PRESS LTDISSN: Frequency: 1 issue/year

Therapeutics and Clinical Risk Management is a pioneering journal published by DOVE MEDICAL PRESS LTD, dedicated to advancing the fields of medication safety, pharmacology, and clinical risk management through rigorous research and comprehensive reviews. With an impact factor that demonstrates its significance within various disciplines, this Open Access journal has been instrumental since its inception in 2006, promoting the dissemination of knowledge to a global audience without barriers. With its reach spanning categories such as Pharmacology, Medicine, and Chemical Health and Safety, it champions innovative practices and risk assessment methodologies. The journal is recognized in the Q2 quartile for multiple related categories and excels in rank within its field, highlighting its influential contributions to safety and therapeutic practices. By prioritizing the sharing of impactful research, Therapeutics and Clinical Risk Management serves as an indispensable resource for researchers, professionals, and students aiming to enhance clinical outcomes and mitigate risks in therapeutic paradigms.

BMC Pharmacology & Toxicology

Unveiling the complexities of drug action and safety.
Publisher: BMCISSN: Frequency: 1 issue/year

Welcome to BMC Pharmacology & Toxicology, a premier open-access journal dedicated to advancing the fields of pharmacology and toxicology. Published by BMC since 2012, this esteemed journal offers a platform for researchers, professionals, and students to disseminate cutting-edge research and innovative findings that explore the intricate interactions between drugs and biological systems. With its robust Q2 ranking in both general medicine and pharmacology categories for 2023, BMC Pharmacology & Toxicology is recognized for its significant contributions to the academic community, reflected in its strategic positioning within the 61st and 49th percentiles in Scopus rankings for related disciplines. The journal's commitment to open access ensures that vital research is accessible to a global audience, fostering collaboration and informed discussions. We invite you to engage with the latest studies, reviews, and innovative methodologies that shape the future of pharmacological and toxicological sciences.

INTERNATIONAL JOURNAL OF RISK & SAFETY IN MEDICINE

Empowering research for a safer medical future.
Publisher: IOS PRESSISSN: 0924-6479Frequency: 4 issues/year

INTERNATIONAL JOURNAL OF RISK & SAFETY IN MEDICINE, published by IOS Press, serves as an essential platform for advancing the understanding of risk and safety within the medical domain. With an ISSN of 0924-6479 and E-ISSN of 1878-6847, this journal has been dedicated to fostering critical discourse since its inception in 1990, reflecting a continuous commitment to the field through 2024. Positioned within the Q4 category in Health Policy and Q3 in Medicine (miscellaneous) and Public Health, Environmental and Occupational Health, the journal provides valuable insights, empirical research, and theoretical analyses that speak to the diverse challenges faced in medical safety and risk management. Although it operates under a subscription model, the journal remains a vital resource for researchers, healthcare professionals, and students alike, facilitating the exchange of innovative ideas and best practices in health risk assessment. With Scopus ranks indicating its role as a key contributor in its categories, the INTERNATIONAL JOURNAL OF RISK & SAFETY IN MEDICINE continues to shape the landscape of medical safety and policy discussions around the globe.

International Journal of Clinical Pharmacy

Empowering Healthcare through Innovative Pharmaceutical Research
Publisher: SPRINGERISSN: 2210-7703Frequency: 6 issues/year

The International Journal of Clinical Pharmacy, published by Springer, serves as a pivotal platform for advancing research in the fields of Pharmaceutical Science and Pharmacology. This esteemed journal, recognized for its significant impact with an impressive Q1 ranking in Pharmacy and multiple Q2 designations, provides a dedicated space for scholars and practitioners to share innovative findings and methodologies that enhance clinical pharmacy practices. With an international reach and publication spanning from 2011 to 2024, the journal aims to facilitate knowledge exchange among researchers, professionals, and students, ultimately contributing to improved therapeutic outcomes. As an open-access journal, it promotes widespread dissemination of vital research, ensuring that cutting-edge clinical pharmacy knowledge is accessible to all stakeholders in the healthcare continuum.

European Journal of Hospital Pharmacy

Connecting Research and Practice in Hospital Pharmacy
Publisher: BMJ PUBLISHING GROUPISSN: 2047-9956Frequency: 6 issues/year

The European Journal of Hospital Pharmacy, published by the prestigious BMJ PUBLISHING GROUP, stands as a vital resource in the field of pharmacy, specifically focused on practices within hospital settings. With its ISSN 2047-9956 and E-ISSN 2047-9964, this journal provides an essential platform for researchers, practitioners, and students to disseminate and access high-quality research that influences clinical practice. Recognized for its significant impact, the journal has achieved a commendable Q2 ranking in both the Pharmacology, Toxicology and Pharmaceutics (miscellaneous) and Pharmacy categories according to Scopus, highlighting its status within the academic community. The journal is indexed among the top 18% in its category, showcasing innovative research and advancements in the field. While the European Journal of Hospital Pharmacy does not operate under an open-access model, its deep commitment to enhancing pharmaceutical care within European hospital settings remains undeterred. The journal also covers a converged period from 2010 to 2024, providing comprehensive insights into evolving practices and challenges. As a premier publication, it plays an essential role in education and professional development, making it indispensable for those involved in pharmacy and healthcare.

DRUGS IN R&D

Exploring the latest breakthroughs in drug R&D.
Publisher: SPRINGER INT PUBL AGISSN: 1174-5886Frequency: 4 issues/year

DRUGS IN R&D is a premier open access journal dedicated to advancing the field of pharmacology and drug development. Published by Springer International Publishing AG, this journal has been a valuable resource for researchers and professionals since its inception in 1999, contributing critical insights into the pharmacological sciences. With an impressive Impact Factor reflecting its significance, DRUGS IN R&D ranks in the Q2 quartile for Pharmacology, according to 2023 metrics, and ranks #151 out of 313 in the field of pharmacology and toxicology on Scopus. This journal offers an open access format, ensuring high visibility and accessibility of research findings to a global audience, supporting the intrepid pursuit of knowledge in drug research and development. By facilitating comprehensive discussions and innovative research findings, DRUGS IN R&D plays a crucial role in shaping the future landscape of pharmacological studies and advancements.

PHARMAZIE

Transforming pharmaceutical practices through research.
Publisher: AVOXA-MEDIENGRUPPE DEUTSCHER APOTHEKER GMBHISSN: 0031-7144Frequency: 12 issues/year

PHARMAZIE is a prestigious, peer-reviewed journal published by AVOXA-MEDIENGRUPPE DEUTSCHER APOTHEKER GMBH, focusing on the dynamic field of pharmaceutical science since its inception in 1947. With its ISSN 0031-7144 and a current impact factor placing it in the Q2 category of Pharmaceutical Science journals, PHARMAZIE has established itself as a pivotal resource for researchers, practitioners, and students alike. The journal emphasizes the dissemination of high-quality, original research in pharmacology, toxicology, and pharmaceutics, contributing to the advancement of knowledge and innovation in these fields. While currently not open access, the journal maintains a commendable Scopus rank of #94 out of 183 in its category, highlighting its relevance and appeal to the academic community. With a commitment to bridging the gap between research and practical applications, PHARMAZIE plays a crucial role in shaping the future of pharmaceutical practices and policies.

BIOLOGICAL & PHARMACEUTICAL BULLETIN

Advancing the Frontiers of Biomedicine and Drug Development
Publisher: PHARMACEUTICAL SOC JAPANISSN: 0918-6158Frequency: 12 issues/year

BIOLOGICAL & PHARMACEUTICAL BULLETIN, published by the PHARMACEUTICAL SOC JAPAN, is a prominent peer-reviewed journal that serves the fields of medicine, pharmaceutical science, and pharmacology. With an ISSN of 0918-6158 and an E-ISSN of 1347-5215, this publication has been crucial in disseminating innovative research since its inception in 1993, and it continues to contribute significantly to the body of knowledge as it converges towards 2024. Despite being classified as a non-open access journal, it maintains a respectable Q3 ranking in Medicine (miscellaneous) and Q2 in Pharmaceutical Science, highlighting its critical role in advancing scientific discourse in these areas. With Scopus rankings placing it in the 51st percentile for Pharmaceutical Science and 38th percentile for Pharmacology, BIOLOGICAL & PHARMACEUTICAL BULLETIN is an essential resource for researchers, professionals, and students looking to stay abreast of cutting-edge developments and trends in biomedicine and drug development.